Merck & Co., Inc (NYSE:MRK)’s BACE may still make the home run

Posted by Ryan Mandell June 19, 2013 0 Comment 1822 views


Eli Lilly stumbles once again in its journey to finding a useful drug for combating Alzheimer’s. Last year, a couple of late-stage trials for solanezumab, an injectable drug was unsuccessful in meeting primary endpoints in the patients suffering from mild-to-moderate disease. The Eli Lilly drug, called LY2886721, was in its Phase-II trial. The company has blocked the trial as few patients’ tests showed abnormal liver biochemical results. It is commonplace for companies to run numerous liver tests on its clinical trial patients as this is a very common safety issue that affects most drugs. The liver flushes out toxins from the body and the LY2886721 seems to have had a negative effect on it.

This Eli Lilly compound, had never really attracted too much attention. The drug that is being followed with a telescope is Merck & Co., Inc (NYSE:MRK)’s BACE inhibitor. This very recently began its Phase-II/III study with patients suffering from mild-to-moderate Alzheimer’s disease. When Merck announced this last December, it had noted that this was the very first drug with this kind of a mechanism, to move into this clinical research stage. If an issue crops up, it is likely to be uncovered in the phase II section that has 200 patient enrollments.

Advantage Merck
With Eli Lilly out of the way, at least for the moment, Merck might just have that extra lap in front of other runners with MK-8931, Its BACE inhibitor. In its phase 1 trial, MK-8931 had reduced the beta-amyloid amount in the cerebral spinal fluid by over 90%. However, it is not yet known whether this will actually reduce the amyloid plaques that are seen in brains of Alzheimer’s patients. In addition to this, what remains to be seen, is that even if there is a reduction in plaque will that have a clinical effect at all?

Disheartening news? 

Despite all the hurdles, its not like companies are going to beat a retreat. The path to developing a successful Alzheimer’s drug has been strewn with thorns but the rewards will outweigh the failures. From a company’s viewpoint, even drugs that are not very likely to succeed are ones that they will probably lay their bets on.


About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment